Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 3/20 | 0.51 |
| ▸ | CDK4 | P11802 | 3/20 | 0.51 |
| ▸ | CCND1 | P24385 | 3/20 | 0.51 |
| ▸ | CDK9 | P50750 | 3/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.51 |
| ▸ | CDK11A | Q9UQ88 | 3/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 12/20 | 0.49 |
| ▸ | CDK2 | P24941 | 12/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195125 | 0.97 | CCNT1 (0.52) | CCNT1CDK4CCND1CDK9CDK6 | |
| SCHEMBL6192807 | 0.89 | CCNB2 (0.55) | CCNT1CDK4CCND1CDK9CDK6 | |
| SCHEMBL6701026 | 0.88 | CCNA2 (0.54) | CCNT1CDK4CCND1CDK9CDK6 | |
| SCHEMBL6192816 | 0.87 | CCNB2 (0.61) | CCNT1CDK4CCND1CDK9CDK6 | |
| SCHEMBL6195665 | 0.87 | CCNA2 (0.53) | CCNT1CDK4CCND1CDK9CDK6 | |
| SCHEMBL6194606 | 0.87 | CCNT1 (0.53) | CCNT1CDK4CCND1CDK9CDK6 | |
| SCHEMBL6194975 | 0.86 | CCNT1 (0.52) | CCNT1CDK4CCND1CDK9CDK6 | |
| SCHEMBL6194186 | 0.85 | CCNT1 (0.57) | CCNT1CDK4CCND1CDK9CDK6 | |
| SCHEMBL6211465 | 0.85 | CCNA2 (0.56) | CCNT1CDK4CCND1CDK9CDK6 | |
| SCHEMBL6193477 | 0.84 | CCNA2 (0.52) | CCNT1CDK4CCND1CDK9CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594866-A1 | ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES | PFIZER INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040176431-A1 | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004072070-A1 | ANTIPROLIFERATIVE 2-(SULFO-PHENYL)-AMINOTHIAZOLE DERIVATIVES | PFIZER INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176431-A1 | Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use | MKI67, TK1, CDK2 | CCNT1 7/4885CDK4 15/4885CCND1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.